Tacrolimus Concentration Is Effectively Predicted Using Combined Clinical and Genetic Factors in the Perioperative Period of Kidney Transplantation and Associated with Acute Rejection

Table 2

Multivariable mixed effects model for tacrolimus concentration/dose ratio ().

Variable	Percentage change in (95% CI)^a
Anemia	-4.01 (-10.96–3.48)
Postoperative day	0.04 (0.02–0.06)
RBC^b	22.17 (14.98–29.82)
HGB	0.07 (-0.10–0.24)
ALB	2.19 (1.72–2.67)
WZC	27.2 (19.39–35.52)
CYP3A5 genotype (rs776746)^c
Poor metabolizers	Reference
Intermediate metabolizers	-22.39 (-27.82 to -16.56)
Extensive metabolizers	-40.89 (-47.62 to -33.29)
ABCB1 (rs1128503)
TT	Reference
CT	-5.21 (-12.07–2.18)
CC	-11.43 (-20.11 to -1.81)
ABCB1 (rs2032582)
GG	Reference
GA	8.19 (-0.52–17.66)
AA	16.52 (4.11–30.42)
ABCB1 (rs1045642)
TT	Reference
CT	-14.59 (-23.18 to -5.03)
CC	-15.03 (-24.75 to -4.05)
ABCC2 (rs2273697)
GG	Reference
GA	1.97 (-22.92–24.65)
AA	8.98 (-13.14–36.73)
ABCC2 (rs3740066)^d
CC	Reference
CT	5.59 (-7.32–20.29)
TT	14.42 (0.48–30.29)
POR28 (rs1057868)
CC	Reference
CT	-5.41 (-14.41–4.53)
TT	-7.54 (-16.56–2.46)
PXR (rs6785049)
GG	Reference
GA	-6.12 (-15.82–4.68)
AA	-5.90 (-15.22–4.43)

RBC: red blood cell; HGB: Hemoglobin; ALT: alanine aminotransferase; ALB: albumin; WZC: Wuzhi capsule. ^aAnalysis based on log-transformed . Model coefficients were exponentiated to provide the percentage change in for a one-unit change in each covariate, unless otherwise specified. Increases in signify decreased tacrolimus clearance. ^bSerious collinearity between RBC and HCT was observed, and consequently only RBC was retained. ^cPoor metabolizers defined as CYP3A53/3 (GG); intermediate metabolizers defined as CYP3A513 (AG); extensive metabolizers defined as . ^dSerious collinearity between ABCC2 (rs3740066) and ABCC2 (rs717620) was observed, and consequently, only ABCC2 (rs3740066) was retained. .